WHAT IS CLAIMED IS:

1. A compound of Formula (I), or a pharmaceutically acceptable salt thereof:

$$R^2$$
 R^3
 R^4
 R^5
 R^6
 O
 OH
 OH

5 wherein

R¹ is -H, -C₁₋₆ alkyl, -C₃₋₆ cycloalkyl, or -C₁₋₆ alkyl which is substituted with 1 or 2 substituents each of which is independently:

- (1) C₃₋₈ cycloalkyl,
- 10 (2) aryl
 - (3) a 5- or 6-membered saturated or mono-unsaturated heterocyclic ring containing from 1 to 4 heteroatoms independently selected from N, O and S,
 - (4) a 5- or 6-membered heteroaromatic ring containing from 1 to 4 heteroatoms independently selected from N, O and S, or
 - (5) a 9- or 10-membered fused bicyclic heterocycle containing from 1 to 4 heteroatoms independently selected from N, O and S, wherein at least one of the rings is aromatic;

wherein

- (A) each cycloalkyl is optionally substituted with from 1 to 3 substituents, each of which is independently halo, -C₁₋₆ alkyl, or -O-C₁₋₆ alkyl;
- (B) each aryl is optionally substituted with from 1 to 5 substituents each of which is independently
 - -C1_6 alkyl, optionally substituted with from 1 to 3 substituents each of which is independently -OH, -O-C1_6 alkyl, -O-C1_6 haloalkyl, -CN, -NO2, -N(RaRb), -C(=O)N(RaRb), -C(=O)Ra, -CO2Rc, -S(O)nRc, -SO2N(RaRb), -N(Ra)C(=O)Rb, -N(Ra)CO2Rc, -N(Ra)SO2Rc, -N(Ra)SO2N(RaRb), -OC(=O)N(RaRb), or -N(Ra)C(=O)N(RaRb),

15

		(2)	-O-C ₁₋₆ alkyl, optionally substituted with from 1 to 3 substituents
			each of which is independently -OH, -O-C1-6 alkyl, -O-C1-6
			haloalkyl, -S(O)nRc, -C(=O)N(RaRb), -SO2N(RaRb),
			-N(R^a)C(=O) R^b , -N(R^a)CO2 R^c , -N(R^a)SO2 R^c ,
5			$-N(R^a)SO_2N(R^aR^b)$, $-OC(=O)N(R^aR^b)$, or
			$-N(R^a)C(=O)N(R^aR^b),$
		(3)	-C ₁₋₆ haloalkyl,
		(4)	-O-C ₁₋₆ haloalkyl,
		(5)	-OH,
10		(6)	halo,
		(7)	-CN,
		(8)	-NO ₂ ,
		(9)	-N(RaRb),
		(10)	-C(=O)N(RaRb),
15		(11)	-C(=O)R ^a ,
		(12)	-CO ₂ Rc,
		(13)	-SR ^c ,
		(14)	-S(=O)R ^c ,
		(15)	-SO ₂ Rc,
20		(16)	-N(Ra)SO ₂ Rc,
		(17)	$-SO_2N(R^aR^b),$
		(18)	$-N(R^a)C(=O)R^b$, or
		(19)	-N(Ra)CO2Rc;
	(C)	each saturate	d or mono-unsaturated heterocyclic ring is
25		(i)	optionally substituted with from 1 to 5 substituents each of which
			is independently halogen, -C ₁₋₆ alkyl, -C ₁₋₆ haloalkyl, -O-C ₁₋₆
			alkyl, -O-C1-6 haloalkyl, or oxo; and
		(ii)	optionally substituted with 1 or 2 substituents each of which is
			independently aryl or a 5- or 6-membered heteroaromatic ring
30			containing from 1 to 4 heteroatoms independently selected from N,
			O and S; and
	(D)	each heteroar	romatic ring or each fused bicyclic heterocycle is

- optionally substituted with from 1 to 7 substituents each of which is independently halogen, -C₁₋₆ alkyl, -C₁₋₆ haloalkyl, -O-C₁₋₆ alkyl, -O-C₁₋₆ haloalkyl, or oxo; and
- (ii) optionally substituted with 1 or 2 substituents each of which is independently aryl or -C1-6 alkyl-aryl;

 \mathbb{R}^2 is -H or -C₁₋₆ alkyl;

R³ is -H, -C₁₋₆ alkyl, -C₁₋₆ haloalkyl, or -C₁₋₆ alkyl substituted with one of -OH, -O-C₁₋₆
alkyl, -O-C₁₋₆ haloalkyl, -CN, -NO₂, -N(RaRb), -C(=O)N(RaRb), -C(=O)Ra, -CO₂Rc,
-S(O)_nRc, -SO₂N(RaRb), -N(Ra)C(=O)Rb, -N(Ra)CO₂Rc, -N(Ra)SO₂Rc, -N(Ra)SO₂N(RaRb),
-OC(=O)N(RaRb), or -N(Ra)C(=O)N(RaRb);

R4 is:

5

20

- 15 (1) -H,
 - (2) -C₁₋₆ alkyl optionally substituted with one of -OH, -O-C₁₋₆ alkyl, -O-C₁₋₆ haloalkyl, -CN, -NO₂, -N(R^aR^b), -C(=O)N(R^aR^b), -C(=O)R^a, -CO₂R^c, -S(O)_nR^c, -SO₂N(R^aR^b), -N(R^a)-C(R^b)=O, -N(R^a)SO₂R^c, -N(R^a)SO₂N(R^aR^b), -OC(=O)N(R^aR^b), -N(R^a)C(=O)N(R^aR^b), -O-C₁₋₆ alkyl-C(=O)N(R^aR^b), -S-C₁₋₆ alkyl-C(=O)N(R^aR^b), -N(R^a)-C₁₋₆ alkyl-C(=O)N(R^aR^b), or -N(SO₂R^c)-C₁₋₆ alkyl-C(=O)N(R^aR^b),
 - (3) -C₁₋₆ haloalkyl,
 - $(4) \quad -C(=O)Ra,$
 - (5) -CO₂Rc,
- 25 (6) $-C(=O)N(R^{a}R^{b}),$
 - $(7) -SO_2N(RaRb),$
 - (8) -C₂₋₆ alkenyl,
 - (9) $-C_{2-6}$ alkenyl-C(=0)-N(Ra)₂,
 - (10) -C2-5 alkynyl,
 - (11) -C₂₋₅ alkynyl-CH₂N(R^a)₂,
 - (12) -C2-5 alkynyl-CH2ORa,
 - (13) $-C_{2-5}$ alkynyl-CH₂S(O)_nR^c, or
 - (14) - \mathbb{R}^{k} ,
 - (15) -C1-6 alkyl substituted with Rk,

((16)) -Ci	6 haloalky	vi substitr	ited with Rk,
1	LV.	,	-D navanz	AT OUTSHEE	TOOM MINT T/'

- (17) $-C_{1-6}$ alkyl-O-Rk,
- (18) -C₁₋₆ alkyl-O-C₁₋₆ alkyl-R^k,
- (19) $-C_{1-6}$ alkyl-S(O)_n-R^k,
- (20) $-C_{1-6}$ alkyl-S(O)_n-C₁₋₆ alkyl-R^k,
- (21) $-C_{1-6}$ alkyl-N(Ra)-Rk,
- (22) $-C_{1-6}$ alkyl-N(Ra)- C_{1-6} alkyl-Rk,
- -C₁₋₆ alkyl-N(R^a)-C₁₋₆ alkyl-OR^k, with the proviso that the -N(R^a)- moiety and the -OR^k moiety are not both attached to the same carbon of the -C₁₋₆ alkyl-moiety,
- (24) $-C_{1-6}$ alkyl-C(=0)-R^k,
- (25) $-C_{1-6}$ alkyl-C(=0)N(Ra)-Rk,
- (26) $-C_{1-6}$ alkyl-N(Ra)C(=O)-Rk,
- (27) -C₁₋₆ alkyl-C(=O)N(R^a)-C₁₋₆ alkyl-R^k, or
- 15 (28) -C₁₋₆ alkyl-N(\mathbb{R}^a)-C₀₋₆ alkyl-S(O)_n \mathbb{R}^k ; wherein \mathbb{R}^k is
 - (i) aryl, which is optionally substituted with from 1 to 5 substituents each of which is independently -C₁₋₆ alkyl, -C₁₋₆ alkyl-OH, -C₁₋₆ alkyl-O-C₁₋₆ alkyl, -C₁₋₆ alkyl-O-C₁₋₆ haloalkyl, -C₁₋₆ alkyl-N(R^aR^b), -C₁₋₆ alkyl-C(=O)N(R^aR^b), -C₁₋₆ alkyl-C(=O)R^a, -C₁₋₆ alkyl-CO₂R^c, -C₁₋₆ alkyl-S(O)_nR^c, -O-C₁₋₆ alkyl, -C₁₋₆ haloalkyl, -O-C₁₋₆ haloalkyl, -OH, halo, -N(R^aR^b), -C(=O)N(R^aR^b), -C(=O)R^a, -CO₂R^c, -S(O)_nR^c, or -SO₂N(R^aR^b);
 - (ii) a 4- to 7-membered saturated or mono-unsaturated heterocyclic ring containing at least one carbon atom and from 1 to 4 heteroatoms independently selected from N, O and S, wherein the heterocyclic ring is:
 - (a) optionally substituted with from 1 to 5 substituents each of which is independently halogen, -C₁₋₆ alkyl, -C₁₋₆ haloalkyl, -O-C₁₋₆ alkyl, -O-C₁₋₆ haloalkyl, or oxo; and
 - (b) optionally mono-substituted with aryl or HetA; wherein HetA is a 5- or 6-membered heteroaromatic ring containing from 1 to 4 heteroatoms independently selected from N, O and S, wherein the heteroaromatic ring is optionally fused with a benzene ring, and HetA is optionally substituted with from 1 to 4

25

20

5

10

substituents each of which is independently $-C_{1-6}$ alkyl, $-C_{1-6}$ haloalkyl, $-O-C_{1-6}$ alkyl, $-O-C_{1-6}$ haloalkyl, or oxo; or

(iii) a 5- or 6-membered heteroaromatic ring containing from 1 to 4 heteroatoms independently selected from N, O and S, wherein the heteroaromatic ring is optionally substituted with from optionally substituted with from 1 to 4 substituents each of which is independently -C1-6 alkyl, -C1-6 haloalkyl, -O-C1-6 alkyl, -O-C1-6 haloalkyl, or oxo;

 R^5 is -H or -C₁₋₆ alkyl;

10

5

R6 is:

- (1) -OH,
- (2) -O-C₁₋₆ alkyl,
- (3) -N(RuRv),
- 15 (4) -O-C₁-6 haloalkyl,
 - (5) -O-C₁₋₆ alkyl-aryl
 - (6) -O-C₁₋₆ alkyl-HetB, or
 - (7) -O-C₁₋₆ alkyl-HetC,

wherein

20

25

30

Ru is -H or -C1-6 alkyl;

Rv independently has the same definition as R1;

HetB is a 5- or 6-membered saturated or mono-unsaturated ring containing from 1 to 4 heteroatoms independently selected from N, O and S, wherein the ring is optionally substituted with from 1 to 5 substituents each of which is independently halogen, -C1-6 alkyl, -C1-6 haloalkyl, -O-C1-6 alkyl, -O-C1-6 haloalkyl, or oxo; and

HetC is a 5- or 6-membered heteroaromatic ring containing from 1 to 4 heteroatoms independently selected from N, O and S, wherein the heteroaromatic ring is optionally substituted with from 1 to 4 substituents each of which is independently -C1-6 alkyl, -C1-6 haloalkyl, -O-C1-6 alkyl, -O-C1-6 haloalkyl, or oxo;

each Ra and Rb is independently -H or -C1-6 alkyl;

each Rc is independently a -C1-6 alkyl; and

each n is independently an integer equal to 0, 1 or 2.

5 2. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein:

R1 is -C1-4 alkyl mono-substituted with aryl; wherein the aryl is optionally substituted with from 1 to 4 substituents each of which is independently

- 10 (1) -C₁₋₄ alkyl, optionally mono-substituted with -OH, -O-C₁₋₄ alkyl, -O-C₁₋₄ haloalkyl, -CN, -N(RaRb), -C(=O)N(RaRb), -C(=O)Ra, -CO₂Rc, -S(O)_nRc, -SO₂N(RaRb), -N(Ra)C(=O)Rb, -N(Ra)CO₂Rc, -N(Ra)SO₂Rc, -N(Ra)SO₂N(RaRb), -OC(=O)N(RaRb), or -N(Ra)C(=O)N(RaRb),
- (2) -O-C₁₋₄ alkyl, optionally mono-substituted with -OH, -O-C₁₋₄ alkyl, -O-C₁₋₄

 15 haloalkyl, -S(O)_RRc, -N(Ra)-CO₂Rc, -C(=O)N(RaRb), -SO₂N(RaRb),
 -N(Ra)C(=O)Rb, -N(Ra)CO₂Rc, -N(Ra)SO₂Rc, -N(Ra)SO₂N(RaRb),
 -OC(=O)N(RaRb), or -N(Ra)C(=O)N(RaRb),
 - (3) -C₁₋₄ haloalkyl,
 - (4) -O-C₁₋₄ haloalkyl,
- 20 (5) -OH,
 - (6) halo,
 - (7) -CN,
 - (8) -NO₂,
 - (9) -N(RaRb),
- 25 (10) -SRc,
 - (11) $-S(=O)R^{c}$,
 - (12) -SO₂R^c,
 - (13) $-N(R^a)SO_2R^c$,
 - (14) -SO₂N(RaRb),
- 30 (15) $-N(R^a)C(=O)R^b$, or
 - (16) -N(Ra)CO₂Rc; and

R6 is:

(1) -OH,

- (2) -O-C₁₋₆ alkyl,
- (3) -N(RuRv),
- (4) -O-C1-6 haloalkyl,
- (5) -O-C₁₋₆ alkyl-aryl
- (6) -O-C1-6 alkyl-HetB, or
- (7) -O-C₁₋₆ alkyl-HetC,

wherein

5

10

15

20

Ru is -H or -C1-6 alkyl;

 R^{V} is -H, -C₁₋₆ alkyl, -C₃₋₆ cycloalkyl, or independently has the same definition as R^{1} above;

HetB is a 5- or 6-membered saturated or mono-unsaturated ring containing from 1 to 4 heteroatoms independently selected from N, O and S, wherein the ring is optionally substituted with from 1 to 5 substituents each of which is independently halogen, -C₁₋₆ alkyl, -C₁₋₆ haloalkyl, -O-C₁₋₆ alkyl, -O-C₁₋₆ haloalkyl, or oxo; and

HetC is a 5- or 6-membered heteroaromatic ring containing from 1 to 4 heteroatoms independently selected from N, O and S, wherein the heteroaromatic ring is optionally substituted with from 1 to 4 substituents each of which is independently -C₁₋₆ alkyl, -C₁₋₆ haloalkyl, -O-C₁₋₆ alkyl, -O-C₁₋₆ haloalkyl, or oxo.

- 3. The compound according to claim 2, or a pharmaceutically acceptable salt thereof, wherein in R¹ is -(CH₂)₁₋₄-phenyl, wherein the phenyl is optionally substituted with from 1 to 3 substituents each of which is independently
- 25 (1) -C₁₋₄ alkyl, optionally mono-substituted with -OH, -O-C₁₋₄ alkyl, -O-C₁₋₄ haloalkyl, -CN, -N(RaRb), -C(=O)N(RaRb), -C(=O)Ra, -CO₂Rc, -S(O)_nRc, or -SO₂N(RaRb),
 - (2) -O-C₁₋₄ alkyl,
 - (3) -C₁₋₄ haloalkyl,
- 30 (4) -O-C₁₋₄ haloalkyl,
 - (5) -OH,
 - (6) halo,
 - (7) -CN,
 - (8) $-NO_{2}$

- (9) -N(RaRb),
- (10) -SRc,

5

- (11) $-S(=O)R^{c}$,
- (12) -SO₂Rc,
- (13) -N(Ra)SO2Rc,
- (14) -SO₂N(RaRb),
- (15) $-N(R^a)C(=O)R^b$, or
- (16) -N(Ra)CO₂Rc.
- 10 4. The compound according to claim 3, or a pharmaceutically acceptable salt thereof, wherein R¹ is:

wherein X1 and X2 are each independently

- 15 (1) -H,
 - (2) methyl,
 - (3) ethyl,
 - (4) methoxy,
 - (5) ethoxy,
 - (6) -CF₃,
 - (7) fluoro,
 - (8) bromo, or
 - (9) chloro.
- 5. The compound according to claim 4, or a pharmaceutically acceptable salt thereof, wherein R¹ is 4-fluorobenzyl.
 - 6. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein:

R² is -H or -C₁₋₄ alkyl;

R3-is -H or -C1-4 alkyl;

- 5 R⁴ is:
- (1) -H,
- -C₁₋₄ alkyl optionally substituted with one of -OH, -O-C₁₋₄ alkyl, -O-C₁₋₄ haloalkyl, -CN, -N(RaRb), -C(=O)N(RaRb), -C(=O)Ra, -CO₂Rc, -S(O)_nRc, -SO₂N(RaRb), -N(Ra)-C(Rb)=O, -N(Ra)SO₂Rb, or -N(Ra)SO₂N(RaRb),
- $^{2}10$ (3) -C(=O)N(RaRb),
 - $(4) \mathbf{R}^{\mathbf{k}},$
 - (5) -C1-4 alkyl substituted with Rk,
 - (6) -C₁₋₄ alkyl-O-R^k, or
 - (7) -C₁₋₄ alkyl-O-C₁₋₄ alkyl-R^k; and

15

R⁵ is -H.

- 7. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein R^6 is:
- 20 (1) -OH,
 - (2) -O-C₁₋₄ alkyl,
 - (3) -N(RuRv),
 - (4) -O-C₁₋₄ haloalkyl,
 - (5) -O-C₁₋₄ alkyl-aryl
 - (6) -O-C_{I-4} alkyl-HetB, or
 - (7) -O-C₁₋₄ alkyl-HetC,

wherein

R^{II} is -H or -C₁₋₄ alkyl;

Ry is -H, -C1-4 alkyl, or cyclopropyl;

30

25

HetB is a 5- or 6-membered saturated ring containing a total of from 1 to 4 heteroatoms independently selected from 1 to 4 N atoms, from 0 to 2 O atoms, and from 0 to 2 S atoms, wherein the saturated ring is optionally substituted with from 1 to 4 substituents each of which is independently halogen, -C1-4 alkyl, -C1-4 haloalkyl, -O-C1-4 alkyl, -O-C1-4 haloalkyl, or oxo; and

HetC is a 5- or 6-membered heteroaromatic ring containing a total of from 1 to 4 heteroatoms independently selected from 1 to 4 N atoms, from 0 to 2 O atoms, and from 0 to 2 S atoms, wherein the heteroaromatic ring is optionally substituted with from 1 to 3 substituents each of which is independently -C₁₋₄ alkyl, -C₁₋₄ haloalkyl, -O-C₁₋₄ alkyl, -O-C₁₋₄ haloalkyl, or oxo.

8. A compound of Formula (II), or a pharmaceutically acceptable salt thereof:

wherein:

10

15

5

X1' and X2' are each independently:

- (1) -H,
- (2) C₁₋₄ alkyl,
- (2) -O-C_{I-4} alkyl,
- (3) -C₁₋₄ haloalkyl,
 - (4) -O-C₁₋₄ haloalkyl, or
 - (5) halo; and

R6' is:

20

25

- (1) -OH,
- (2) -O-C₁₋₄ alkyl, or
- (3) -N(RuRv);

wherein

Ru is -H or -C1-4 alkyl; and

Rv is -C1_4 alkyl or cyclopropyl.

9. A compound according to claim 8, or a pharmaceutically acceptable salt thereof, wherein:

wherein X1' and X2' are each independently:

- (1) -H,
- (2) methyl,
- (2) -OCH₃,
- (3) -CF₃,
 - (4) -OCF3,
 - (5) chloro,
 - (6) fluoro, or
 - (7) bromo; and

10

15

5

R6' is:

- (1) -OH,
- (2) methoxy
- (3) ethoxy
- (4) $-N(R^{U}R^{V});$

wherein

Ru is -H; and

Rv is methyl, ethyl, or cyclopropyl.

20 10. The compound according to claim 8, which is a compound of Formula (III), or a pharmaceutically acceptable salt thereof:

wherein $X^{1'}$ and $X^{2'}$ are each independently -H or halo.

25 11. The compound according to claim 10, or a pharmaceutically acceptable salt thereof, wherein

X11 and X21 are each independently -H, fluoro, chloro, or bromo; and

30 R6' is:

- (1) -OH,
- (2) methoxy
- (3) ethoxy
- (4) $-N(R^{\perp}R^{\vee});$

5 wherein

Ru is -H; and

R^v is methyl, ethyl, or cyclopropyl.

12. A compound according to claim 1, or a pharmaceutically acceptable salt thereof, which is a compound of Formula (IV):

wherein

Ru is -H or -C1-6 alkyl;

15

20

25

RV is C1-6 alkyl which is substituted with 1 or 2 substituents each of which is independently:

- (1) C₃₋₈ cycloalkyl,
- (2) aryl,
- (3) a 5- or 6-membered saturated or mono-unsaturated heterocyclic ring containing from 1 to 4 heteroatoms independently selected from N, O and S,
- (4) a 5- or 6-membered heteroaromatic ring containing from 1 to 4 heteroatoms independently selected from N, O and S, or
- (5) a 9- or 10-membered fused bicyclic heterocycle containing from 1 to 4 heteroatoms independently selected from N, O and S, wherein at least one of the rings is aromatic;

wherein

 (A) each cycloalkyl is optionally substituted with from 1 to 3 substituents, each of which is independently halo, -C₁₋₆ alkyl, or -O-C₁₋₆ alkyl;

	(B)	each aryl is o	ptionally substituted with from 1 to 5 substituents each of which is
		independently	y
		(1)	-C1-6 alkyl, optionally substituted with from 1 to 3 substituents
			each of which is independently -OH, -O-C1-6 alkyl, -O-C1-6
5			haloalkyl, -CN, -NO2, -N(RaRb), -C(=O)N(RaRb), -C(=O)Ra,
			$-CO_2R^c$, $-S(O)_{\Pi}R^c$, $-SO_2N(R^aR^b)$, $-N(R^a)C(=O)R^b$,
			$-N(R^a)CO_2R^c$, $-N(R^a)SO_2R^c$, $-N(R^a)SO_2N(R^aR^b)$,
			-OC(=O)N(RaRb), or $-N(Ra)C(=O)N(RaRb)$,
•		(2)	-O-C1-6 alkyl, optionally substituted with from 1 to 3 substituents
10			each of which is independently -OH, -O-C1-6 alkyl, -O-C1-6
			haloalkyl, $-S(O)_nR^c$, $-C(=O)N(R^aR^b)$, $-SO_2N(R^aR^b)$,
			$-N(R^a)C(=O)R^b$, $-N(R^a)CO_2R^c$, $-N(R^a)SO_2R^c$,
			-N(Ra)SO2N(RaRb), -OC(=O)N(RaRb), or
			$-N(R^a)C(=O)N(R^aR^b),$
15		(3)	-C ₁₋₆ haloalkyl,
		(4)	-O-C ₁₋₆ haloalkyl,
		(5)	-OH,
		(6)	halo,
		(7)	-CN,
20		(8)	-NO ₂ ,
		(9)	-N(RaRb),
		(10)	-C(=O)N(RaRb),
		(11)	-C(=O)Ra,
		(12)	-CO ₂ Rc,
25		(13)	-SRc,
		(14)	-S(=O)R ^c ,
		(15)	-SO ₂ R¢,
		(16)	-N(Ra)SO ₂ Rc,
		(17)	-SO ₂ N(RaRb),
30		(18)	-N(Ra)C(=O)Rb, or
		(19)	-N(Ra)CO ₂ Rc;
	(C)	oooh oomisoto	1

(i) optionally substituted with from 1 to 5 substituents each of which is independently halogen, -C₁₋₆ alkyl, -C₁₋₆ haloalkyl, -O-C₁₋₆ alkyl, -O-C₁₋₆ haloalkyl, or oxo; and

5

 (ii) optionally substituted with 1 or 2 substituents each of which is independently aryl or a 5- or 6-membered heteroaromatic ring containing from 1 to 4 heteroatoms independently selected from N, O and S; and

(D) each heteroaromatic ring or each fused bicyclic heterocycle is

10

- (i) optionally substituted with from 1 to 7 substituents each of which is independently halogen, -C₁₋₆ alkyl, -C₁₋₆ haloalkyl, -O-C₁₋₆ alkyl, -O-C₁₋₆ haloalkyl, or oxo; and
- (ii) optionally substituted with 1 or 2 substituents each of which is independently aryl or -C1-6 alkyl-aryl; and
- 15 R¹ is -H or -C₁-6 alkyl.
 - 13. The compound according to claim 12, or a pharmaceutically acceptable salt thereof, wherein RY is -C₁_4 alkyl mono-substituted with aryl; wherein the aryl is optionally substituted with from 1 to 4 substituents each of which is independently

20

(1) -C₁₋₄ alkyl, optionally mono-substituted with -OH, -O-C₁₋₄ alkyl, -O-C₁₋₄ haloalkyl, -CN, -N(RaRb), -C(=O)N(RaRb), -C(=O)Ra, -CO₂Rc, -S(O)_nRc, -SO₂N(RaRb), -N(Ra)C(=O)Rb, -N(Ra)CO₂Rc, -N(Ra)SO₂Rc, -N(Ra)SO₂N(RaRb), -OC(=O)N(RaRb), or -N(Ra)C(=O)N(RaRb),

25


- -O-C₁₋₄ alkyl, optionally mono-substituted with -OH, -O-C₁₋₄ alkyl, -O-C₁₋₄ haloalkyl, -S(O)_nR^c, -N(R^a)-CO₂R^c, -C(=O)N(R^aR^b), -SO₂N(R^aR^b), -N(R^a)C(=O)R^b, -N(R^a)CO₂R^c, -N(R^a)SO₂R^c, -N(R^a)SO₂N(R^aR^b), -OC(=O)N(R^aR^b), or -N(R^a)C(=O)N(R^aR^b),
- (3) -C₁₋₄ haloalkyl,
- (4) -O-C₁₋₄ haloalkyl,

- (5) -OH,
- (6) halo,
- (7) -CN,
- (8) $-NO_{2}$
- (9) -N(RaRb),

(10) -SRc,

5

- (11) $-S(=O)R^{c}$,
- (12) -SO₂Rc,
- (13) $-N(R^a)SO_2R^c$,
- (14) $-SO_2N(RaR^b)$,
 - (15) $-N(R^a)C(=O)R^b$, or
 - (16) -N(Ra)CO2Rc.
- The compound according to claim 13, or a pharmaceutically acceptable also salt thereof, wherein RV is:



wherein X^1 and X^2 are each independently

- (1) -H,
- 15 (2) methyl,
 - (3) ethyl,
 - (4) methoxy,
 - (5) ethoxy,
 - (6) -CF3,
- 20 (7) fluото,
 - (8) bromo, or
 - (9) chloro.
- 15. The compound according to claim 14, or a pharmaceutically acceptable salt thereof, wherein R^v is 4-fluorobenzyl.
 - 16. The compound according to claim 12, or a pharmaceutically acceptable salt thereof, wherein:
- 30 Ru is -H;

R⁵ is -H;

R4 is:

5 (1)

- (2) -C₁₋₄ alkyl optionally substituted with one of -OH, -N(RaRb), or -C(=O)N(RaRb),
- (3) -C(=O)N(RaRb),
- (4) $-(CH_2)_{1-3}-R^k$,

-H,

- 10 (5) -(CH₂)₁₋₃-O-R^k, or
 - (6) $-(CH_2)_{1-3}-O-(CH_2)_{1-3}-R^k$;

R² is -H; and

15 R¹ is -C₁-4 alkyl.

17. A compound selected from the group consisting of:

10

WO 2004/047725

5

and pharmaceutically acceptable salts thereof.

- 18. A pharmaceutical composition comprising a therapeutically effective
 amount of a compound according to claim 1, or a pharmaceutically acceptable salt thereof, and a
 pharmaceutically acceptable carrier.
 - 19. A method of inhibiting HIV integrase in a subject in need thereof which comprises administering to the subject a therapeutically effective amount of the compound according to claim 1, or a pharmaceutically acceptable salt thereof.
 - 20. A method for preventing or treating infection by HIV or for preventing, treating or delaying the onset of AIDS in a subject in need thereof which comprises administering to the subject a therapeutically effective amount of the compound according to claim 1, or a pharmaceutically acceptable salt thereof.
 - 21. A pharmaceutical composition which comprises the product prepared by combining an effective amount of a compound according to claim 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

25

15

20

22. A combination useful for inhibiting HIV integrase, for treating or preventing infection by HIV, or for preventing, treating or delaying the onset of AIDS, which is a therapeutically effective amount of a compound according to claim 1, or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of an HIV infection/AIDS antiviral agent selected from the group consisting of HIV protease inhibitors, non-nucleoside HIV reverse transcriptase inhibitors and nucleoside HIV reverse transcriptase inhibitors.

This Page is Inserted by IFW Indexing and Scanning Operations and is not part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

BLACK BORDERS

IMAGE CUT OFF AT TOP, BOTTOM OR SIDES

FADED TEXT OR DRAWING

BLURRED OR ILLEGIBLE TEXT OR DRAWING

SKEWED/SLANTED IMAGES

COLOR OR BLACK AND WHITE PHOTOGRAPHS

GRAY SCALE DOCUMENTS

LINES OR MARKS ON ORIGINAL DOCUMENT

REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY

IMAGES ARE BEST AVAILABLE COPY.

☐ OTHER: ____

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.